0001193125-24-172410.txt : 20240628 0001193125-24-172410.hdr.sgml : 20240628 20240628170457 ACCESSION NUMBER: 0001193125-24-172410 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240628 FILED AS OF DATE: 20240628 DATE AS OF CHANGE: 20240628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectis S.A. CENTRAL INDEX KEY: 0001627281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36891 FILM NUMBER: 241086707 BUSINESS ADDRESS: STREET 1: 8 RUE DE LA CROIX JARRY CITY: PARIS, LLE-DE-FRANCE STATE: I0 ZIP: 75013 BUSINESS PHONE: 33181691600 MAIL ADDRESS: STREET 1: 8 RUE DE LA CROIX JARRY CITY: PARIS, LLE-DE-FRANCE STATE: I0 ZIP: 75013 6-K 1 d836253d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

Date of Report: June 28, 2024

Commission File Number: 001-36891

 

 

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

 

 

8, rue de la Croix Jarry

75013 Paris, France

+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

 

 

 


Cellectis S.A.

Cellectis S.A. (the “Company”) held its Combined General Meeting of Shareholders (the “Meeting”) on June 28, 2024.

The voting results of the Meeting, which is attached as Exhibit 99.1 hereto, is incorporated by reference herein.

EXHIBITS

 

Exhibit   

Title

99.1    Voting Results for the Combined General Meeting of Shareholders


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    CELLECTIS S.A.
June 28, 2024     By:  

/s/ André Choulika

      André Choulika
      Chief Executive Officer
EX-99.1 2 d836253dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

CELLECTIS ANNUAL SHAREHOLDERS MEETING – June 28. 2024

VOTE RESULTS

Ordinary Resolutions

 

NB

   Resolution      Result      For    

 

Against

    Vote whithhold      Total votes      Shares
represented
by the
votes cast
     Percentage of the
share capital
represented by the
votes cast
    Out of
voting
rights
     Null voting
rights
     Quorum  
   Votes      %     Votes      %     Votes      %  

1

     approval of the annual financial statements for the financial year ended December 31,2023  
     1        carried        45 182 051        99.60     179 689        0.40     17 048        —         45 361 740        40 493 776        40.455     0        0        40.455

2

     approval of the consolidated financial statements for the financial year ended December 31, 2023  
     2        carried        45 164 516        99.60     180 689        0.40     33 583        —         45 345 205        40 493 776        40.455     0        0        40.455

3

     allocation of the results for the financial year ended December 31,2023  
     3        carried        45 178 716        99.60     180 489        0.40     19 583        —         45 359 205        40 493 776        40.455     0        0        40.455

4

     allocation of losses carried forward to the “share premium” account  
     4        carried        45 070 113        99.36     288 592        0.64     20 083        —         45 358 705        40 493 776        40.455     0        0        40.455

5

     review of the agreements considered in articles L. 225-38 et seq. of the French Commercial Code (financing agreement with Bpifrance)  
     5        carried        36 404 916        99.45     201 042        0.55     20 083        —         36 605 958        34 620 529        34.588     8 752 747        0        40.455

 

1/5


CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

 

NB

   Resolution      Result      For    

 

Against

    Vote whithhold      Total votes      Shares
represented
by the
votes cast
     Percentage of the
share capital
represented by the
votes cast
    Out of
voting
rights
     Null voting
rights
     Quorum  
   Votes      %     Votes      %     Votes      %  

6

     review of the agreements considered in articles L. 225-38 et seq. of the French Commercial Code (subsidy and repayable advance agreement with Bpifrance)  
     6        carried        36 402 945        99.45     203 013        0.55     20 083        —         36 605 958        34 620 529        34.588     8 752 747        0        40.455

7

     renewal of the appointment of Mr. André Choulika as a member of the board of directors  
     7        carried        44 631 510        98.39     729 346        1.61     17 932        —         45 360 856        40 493 776        40.455     0        0        40.455

8

     renewal of the appointment of Mr. David Sourdive as a member of the board of directors  
     8        carried        43 090 151        94.99     2 270 705        5.01     17 932        —         45 360 856        40 493 776        40.455     0        0        40.455

9

     renewal of the appointment of J.M.H. Conseil as statutory auditor  
     9        carried        33 583 149        76.76     10 169 651        23.24     1 625 988        —         43 752 800        40 493 776        40.455     0        0        40.455

10

     appointment of KPMG as statutory auditor  
     10        carried        45 156 134        99.55     204 746        0.45     17 908        —         45 360 880        40 493 776        40.455     0        0        40.455

11

     authorization to the Board of Directors to buy back shares of the Company  
     11        carried        44 846 482        98.87     514 375        1.13     17 931        —         45 360 857        40 493 776        40.455     0        0        40.455

12

     authorization to be granted to the Board of Directors to reduce the share capital by cancelling shares under the authorization for to buy back its own shares  
     12        carried        45 052 759        99.33     305 495        0.67     20 534        —         45 358 254        40 493 776        40.455     0        0        40.455

 

2/5


CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

Extraordinary Resolutions

 

   Résolution      Résultat      Pour    

 

 

Contre

    Abstention      Total des voix
prises en compte
     Actions
représentées
par les voix
exprimées
     Proportion
du capital
social
représenté
par les voix
exprimées
    Voix exclues      Voix nulles      Quorum  
   Votes      %     Votes      %     Votes      %  

13

     up-date of Article 24 of the articles of association “Loss of one half of share capital” in order to comply with legal provisions  
     13        carried        45 151 875        99.55     206 370        0.45     20 543        —         45 358 245        40 493 776        40.455     0        0        40.455

14

    

delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares
and/or any securities. with cancellation of shareholders’ preferential subscription rights in favor of the European Investment Bank or of other entities
that may succeed EIB. according to any finance agreement entered or be entered
 
 
 
     14        carried        43 926 971        96.87     1 418 183        3.13     33 634        —         45 345 154        40 493 776        40.455     0        0        40.455

15

    

delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares
and/or any securities, with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified
characteristics (investors with experience in the health or biotech sector)
 
 
 
     15        carried        44 978 073        99.16     381 081        0.84     19 634        —         45 359 154        40 493 776        40.455     0        0        40.455

16

    

delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares or
any securities. with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics
(credit institutions. investment services providers or members of an investment pool guaranteeing the completion of the considered issue)
 
 
 
     16        carried        44 971 324        99.14     388 551        0.86     18 913        —         45 359 875        40 493 776        40.455     0        0        40.455

17

    

delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares or
any other securities, with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified
characteristics (industrial companies. institutions or entities active in the health or biotechnology sector)
 
 
 
     17        carried        44 957 300        99.14     388 511        0.86     32 977        —         45 345 811        40 493 776        40.455     0        0        40.455

 

3/5


CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

 

   Résolution      Résultat      Pour    

 

 

Contre

    Abstention      Total des voix
prises en compte
     Actions
représentées
par les voix
exprimées
     Proportion
du capital
social
représenté
par les voix
exprimées
    Voix exclues      Voix nulles      Quorum  
   Votes      %     Votes      %     Votes      %  

18

    

delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with
cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics the framework of an
equity or bond financing agreement
 
 
 
     18        carried        44 971 364        99.14      388 511        0.86      18 913        —         45 359 875        40 493 776        40.455      0        0        40.455 

19

    

delegation of authority to be granted to the Board of Directors to decide on the issuance of ordinary shares to be issued immediately or in the future
by the Company. with cancellation of the shareholders’ preferential subscription rights, to the benefit of a category of persons meeting specified
characteristics within the framework of an equity financing program on the American market known as “At-the-market” or “ATM”
 
 
 
     19        carried        44 957 603        99.14      388 511        0.86      32 674        —         45 346 114        40 493 776        40.455      0        0        40.455 

20

    
delegation of authority to be granted to the Board of Directors to immediately or in the future increase the share capital by issuing ordinary shares or
any other securities giving access to the share capital. with the shareholders’ preferential subscription rights maintained
 
 
     20        carried        45 029 850        99.28      328 304        0.72      20 634        —         45 358 154        40 493 776        40.455      0        0        40.455 

21

    

delegation of authority to be granted to the Board of Directors to increase the capital immediately or in the future through the issue of ordinary
shares or any securities, with cancellation of the shareholders’ pre-emptive subscription rights by way of a public offering (other than the offers
referred to in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code)
 
 
 
     21        carried        44 971 727        99.15      387 411        0.85      19 650        —         45 359 138        40 493 776        40.455      0        0        40.455 

22

    

delegation of authority to be granted to the Board of Directors to increase the capital immediately or in the future through the issue of ordinary
shares or any securities, with cancellation of’ pre-emptive subscription rights by way of an offering referred to in paragraph 1° of Article L. 411-2 of
the French Monetary and Financial Code
 
 
 
     22        carried        44 957 703        99.11     401 451        0.89      19 634        —         45 359 154        40 493 776        40.455      0        0        40.455 

23

    
delegation of authority to be granted to the Board of Directors to increase the amount of each of the issues with or without pre-emptive subscription
rights which will be decided pursuant to the above delegations
 
 
     23        carried        44 981 679        99.17      377 478        0.83      19 631        —         45 359 157        40 493 776        40.455      0        0        40.455 

 

4/5


CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

 

   Résolution      Résultat      Pour    

 

 

Contre

    Abstention      Total des voix
prises en compte
     Actions
représentées
par les voix
exprimées
     Proportion
du capital
social
représenté
par les voix
exprimées
    Voix exclues      Voix nulles      Quorum  
   Votes      %     Votes      %     Votes      %  

24

    

determination of the total amount of the capital increases that may be carried out under the aforementioned delegations (excluding the share capital increase
with upholding of the shareholders’ preferential subscription rights and the share capital increase in favor of the European Investment Bank or of other
entities that may succeed EIB. according to any finance agreement)
 
 
     24        carried        45 149 182        99.54      209 972        0.46      19 634        —         45 359 154        40 493 776        40.455      0        0        40.455 

25

     delegation of authority to be granted to the board of directors to increase the capital by incorporation of premiums. reserves. profits or other  
     25        carried        45 115 130        99.46      244 026        0.54      19 632        —         45 359 156        40 493 776        40.455      0        0        40.455 

26

    
authorization to be granted to the Board of Directors to grant options to subscribe for or purchase ordinary shares in the Company, entailing a waiver by the
shareholders of their preferential subscription rights
 
 
     26        carried        35 196 342        96.19      1 395 967        3.81      8 786 479        —         36 592 309        40 493 776        40.455      0        0        40.455 

27

    
authorization to be granted to the Board of Directors to proceed with free allocations of ordinary shares of the Company, to the benefit of employees and/or
corporate officers of the Company and its subsidiaries, entailing the waiver by the shareholders of their preferential subscription rights
 
 
     27        carried        35 243 114        96.28      1 363 293        3.72      8 772 381        —         36 606 407        40 493 776        40.455      0        0        40.455 

28

    
determination of the total amount of the capital increases that may be carried out by virtue of the aforementioned authorization to grant options to subscribe
for or purchase shares and the aforementioned authorization to grant free shares
 
 
     28        carried        45 137 900        99.51      221 154        0.49      19 734        —         45 359 054        40 493 776        40.455      0        0        40.455 

29

    
delegation of authority to be granted to the Board of Directors for the purpose of carrying out a capital increase whose subscription will be reserved for
members of a company savings plan established pursuant to Articles L. 3332-1 et seq. of the Labor Code
 
 
     29        rejected        9 064 329        19.99      36 287 053        80.01      27 406        —         45 351 382        40 493 776        40.455      0        0        40.455 

 

5/5